Resperate

InterCure is a manufacturer of medical devices used to Lower Blood Pressure. InterCure’s manufacturing is based in Nazareth, Israel with a distribution office in New York, New York. Founded in 2000, InterCure, Inc makes interactive therapeutic devices that have been cleared by the FDA for over-the-counter sales. These therapeutic devices are used for the treatment of high blood pressure. Marketed under the brand name of RESPeRATE, the InterCure Company offers their high blood pressure treatment device for use by physicians as well as for home health care. The InterCure Corporation’s medical device helps people reduce high blood pressure without making them feel weak. Feelings of weakness is a major side effect of using ACE inhibitor drugs for hypertension.

InterCure, Inc. produces a medical device used for the treatment of hypertension. Sold under the brand name of RESPeRATE, InterCure offers a home care blood pressure treatment device that is non-invasive and uses no chemicals or drugs. Approved by the U.S. Food & Drug Administration, InterCure RESPeRATE provides a systematic reduction in sympathetic outflow of the autonomous nervous system. One of the key underlining causes for cardiovascular disease, insomnia and other dangerous health conditions is the autonomous nervous system. Ten separate clinical studies have demonstrated the device’s efficacy and safety. InterCure’s RESPeRATE is now featured in more than 20 popular and professional text books.

Hypertension Studies

• Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-626.
• Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-773.
• Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Leiby BE, Vela-Bueno A, Kales A. Association of hypertension and sleep-disordered breathing. Arch Intern Med. 2000;160:2289-2295.
• Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: Evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med. 2007;167:757-764.
• Lozano L, Tovar JL, Sampol G, Romero O, Jurado MJ, Segarra A, Espinel E, Rios J, Untoria MD, Lloberes P. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: A randomized, controlled trial. J Hypertens. 2010;28:2161-2168.
•  Schein, M.; Gavish, B.; Herz, M.; Rosner-Kahana, D.; Naveh, P.; Knishkowy, B.; Zlotnikov, E.; Ben-Zvi, N.; Melmed, R.N. Treating hypertension with a device that slows and regularizes breathing: A randomized, double-blind controlled study. Journal of Human Hypertension. 2001, 15:271-278.
• Grossman, E.; Grossman, A.; Schein, M.H,; Zimlichman, R.; Gavish, B.; Breathing-control lowers blood pressure. Journal of Human Hypertension; 2001, 15:263-269.
• Viskoper, R.; Shapira, I.; Priluck, R.; Mindlin, R.; Chornia, L.; Laszt, A.; Dicker, D.; Gavish, B.; Alter, A. Non-Pharmacological Treatment of Resistant Hypertensives by Device-Guided Slow Breathing Exercises. American Journal of Hypertension; 2003; 16:484-487.